Melanoma Trial, Recruiting NCT06488365 Sponsor: Cytoastra Condition: Melanoma
Back to Melanoma

Melanoma Trial, Recruiting

NCT06488365
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have a confirmed diagnosis of melanoma, based on a tissue sample examined in a lab.
  • People who have gone through the full informed consent process and signed a consent form, after having all study requirements and possible risks explained to them.
  • People who are able to sit for up to 60 minutes at a time.

Who may not be able to join:

  • People who are unable to give informed consent, such as those with a mental condition that makes it difficult to understand what the study involves and what the possible consequences are.
  • People with serious ongoing health conditions affecting the heart, liver, brain or nervous system, hormonal system, or other major body systems, where participation could put them at risk or make the study difficult to carry out (confirm with trial site).
  • People with a significant or severe infection, whether short-term or ongoing.
  • People who are pregnant, breastfeeding, or planning to become pregnant during the study.
  • Women who could become pregnant and are not using an effective form of contraception, or who are unwilling or unable to be tested for pregnancy.
  • People with a known history of severe, persistent constipation.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Ekaterina Galanzha, PhD, Cytoastra

Phone: 5017658175

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Cytoastra
Registry
ClinicalTrials.gov
Start date
11 February 2025
Est. completion
11 February 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Identify and count CTCs in blood in vivo

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov